{
    "organizations": [],
    "uuid": "bd756a72fe9a5ce7d3d168ff46a53fb12848f447",
    "author": "",
    "url": "https://www.reuters.com/article/brief-intra-cellular-therapies-reports-q/brief-intra-cellular-therapies-reports-q4-loss-per-share-0-56-idUSASB0C89B",
    "ord_in_thread": 0,
    "title": "BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1, 2018 / 12:12 PM / Updated 7 minutes ago BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56 Reuters Staff March 1 (Reuters) - Intra-Cellular Therapies Inc: * INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE * Q4 LOSS PER SHARE $0.56 * CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TOTALED $464.3 MILLION AT DEC 31, 2017, VERSUS $384.1 MILLION AT DEC 31, 2016 * INTRA-CELLULAR THERAPIES - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE USED PRIMARILY TO ADVANCE LUMATEPERONE DEVELOPMENT PROGRAM * INTEND TO SUBMIT A NEW DRUG APPLICATION FOR LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA BY MID-2018 * PRE-NDA MEETING WITH FDA IS SCHEDULED TO BE HELD IN LATE Q1 2018 FOR LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-03-01T14:09:00.000+02:00",
    "crawled": "2018-03-01T14:26:04.063+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapy",
        "report",
        "q4",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "march",
        "reuters",
        "therapy",
        "inc",
        "therapy",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "q4",
        "loss",
        "per",
        "share",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "security",
        "totaled",
        "million",
        "dec",
        "versus",
        "million",
        "dec",
        "therapy",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "security",
        "used",
        "primarily",
        "advance",
        "lumateperone",
        "development",
        "program",
        "intend",
        "submit",
        "new",
        "drug",
        "application",
        "lumateperone",
        "treatment",
        "schizophrenia",
        "meeting",
        "fda",
        "scheduled",
        "held",
        "late",
        "q1",
        "lumateperone",
        "treatment",
        "schizophrenia",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}